Gene Gene synonym Ensembl Gene description Chromosome Position Protein class Evidence Antibody Reliability (IH) Reliability (Mouse Brain) Reliability (IF) Subcellular location Prognostic p-value RNA cancer category RNA tissue category RNA TS RNA TS TPM TPM max in non-specific INSL5 ENSG00000172410 Insulin-like 5 1 66797741-66801256 Predicted secreted proteins Evidence at protein level HPA030100, CAB033849 Supported Group enriched Group enriched 231 colon: 79.8;rectum: 143.8 cerebral cortex,testis: 0.4 AQP8 ENSG00000103375 Aquaporin 8 16 25215731-25228940 Predicted membrane proteins, Transporters Evidence at protein level HPA046259 Approved Group enriched Group enriched 132 colon: 325.1;pancreas: 269.4;rectum: 169.2 smooth muscle: 1.9 MEP1A PPHA ENSG00000112818 Meprin A, alpha (PABA peptide hydrolase) 6 46793390-46839782 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB025163, HPA029416 Supported Tissue enriched Group enriched 41 colon: 120.0;duodenum: 290.0;rectum: 116.2;small intestine: 549.0 appendix: 6.5 PRAC1 C17orf92, PRAC ENSG00000159182 Prostate cancer susceptibility candidate 1 17 48721719-48722522 Predicted intracellular proteins Evidence at transcript level HPA047871 Approved Tissue enriched Group enriched 38 colon: 105.4;prostate: 197.0;rectum: 224.2 urinary bladder: 4.5 ISX RAXLX ENSG00000175329 Intestine-specific homeobox 22 35066136-35087387 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA060328 Approved Supported Nucleoplasm
Nuclear bodies Tissue enhanced Group enriched 37 colon: 27.9;duodenum: 38.5;rectum: 28.6;small intestine: 30.3 smooth muscle: 0.8 CA1 Car1 ENSG00000133742 Carbonic anhydrase I 8 85327608-85379014 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006558, CAB025790 Supported Group enriched Group enriched 31 bone marrow: 1219.6;colon: 1039.5;rectum: 2348.0 smooth muscle: 49.1 TBX10 TBX13, TBX7 ENSG00000167800 T-box 10 11 67631303-67639560 Predicted secreted proteins, Transcription factors Evidence at protein level HPA047881 Uncertain Group enriched Group enriched 27 colon: 9.0;duodenum: 6.0;rectum: 8.8;small intestine: 10.8 appendix,testis: 0.3 BTNL3 BTN9.1, BTNLR ENSG00000168903 Butyrophilin-like 3 5 180988845-181006727 Predicted membrane proteins Evidence at transcript level Group enriched Group enriched 25 colon: 25.0;duodenum: 118.3;rectum: 26.8;small intestine: 90.9 gallbladder: 2.5 MUC12 MUC11 ENSG00000205277 Mucin 12, cell surface associated 7 100969623-101018949 Predicted membrane proteins Evidence at protein level HPA023835 Approved Tissue enriched Group enriched 24 colon: 50.6;rectum: 75.4 appendix: 2.6 TMIGD1 TMIGD, UNQ9372 ENSG00000182271 Transmembrane and immunoglobulin domain containing 1 17 30316333-30334059 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA021946 Approved Mitochondria Tissue enhanced Group enriched 24 colon: 83.2;rectum: 111.5;small intestine: 165.6 kidney: 5.0 KRTAP13-2 KAP13-2 ENSG00000182816 Keratin associated protein 13-2 21 30348075-30425912 Plasma proteins, Predicted intracellular proteins Evidence at protein level Tissue enhanced Group enriched 20 colon: 1.9;rectum: 2.0 all non-specific tissues: 0.0 MS4A12 FLJ20217, Ms4a10 ENSG00000071203 Membrane-spanning 4-domains, subfamily A, member 12 11 60492778-60507430 Predicted membrane proteins Evidence at protein level HPA057657 Supported Tissue enriched Group enriched 19 colon: 239.6;rectum: 284.9 appendix: 14.0 NOX1 GP91-2, MOX1, NOH-1, NOH1 ENSG00000007952 NADPH oxidase 1 X 100843324-100874345 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level Colorectal cancer:9.71e-4 (favourable) Tissue enriched Group enriched 17 colon: 60.0;rectum: 81.1 appendix: 4.0 CD177 HNA2A, NB1, PRV1 ENSG00000204936 CD177 molecule 19 43353659-43363172 Predicted secreted proteins Evidence at protein level HPA041820, HPA046601 Supported Cervical cancer:3.66e-4 (favourable) Tissue enhanced Group enriched 16 bone marrow: 193.4;colon: 159.0;prostate: 110.8;rectum: 184.1 appendix: 10.0 GUCA2A GUCA2, STARA ENSG00000197273 Guanylate cyclase activator 2A (guanylin) 1 42162691-42164718 Plasma proteins, Predicted secreted proteins Evidence at protein level HPA018215 Supported Group enriched Group enriched 15 colon: 782.6;rectum: 872.3;small intestine: 1146.4 duodenum: 63.3 PYY PYY1 ENSG00000131096 Peptide YY 17 43952738-44004469 Predicted secreted proteins Evidence at protein level HPA010973, CAB016734 Supported Group enriched Group enriched 15 colon: 53.7;rectum: 39.9;small intestine: 27.8 duodenum: 2.6 CHST5 FLJ22167, I-GLCNAC-6-ST ENSG00000135702 Carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 5 16 75528535-75535247 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA043804 Approved Group enriched Group enriched 14 colon: 46.8;duodenum: 88.4;rectum: 60.8;small intestine: 85.3 stomach: 4.9 GUCY2C GUC2C, STAR ENSG00000070019 Guanylate cyclase 2C 12 14612632-14696585 Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA037655, HPA073759 Uncertain Uncertain Vesicles Liver cancer:1.37e-5 (unfavourable) Group enriched Group enriched 13 colon: 38.4;duodenum: 70.6;rectum: 48.1;small intestine: 74.7 appendix: 4.5 NAT2 AAC2 ENSG00000156006 N-acetyltransferase 2 (arylamine N-acetyltransferase) 8 18391245-18401218 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA043704 Uncertain Colorectal cancer:4.61e-5 (favourable) Tissue enhanced Group enriched 13 colon: 14.7;duodenum: 33.6;liver: 62.2;rectum: 14.2;small intestine: 27.7 smooth muscle: 2.3 NXPE1 FAM55A, MGC34290 ENSG00000095110 Neurexophilin and PC-esterase domain family, member 1 11 114521715-114559895 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA049133 Supported Tissue enriched Group enriched 13 colon: 114.0;rectum: 168.7 appendix: 11.0 LYPD8 ENSG00000259823 LY6/PLAUR domain containing 8 1 248718649-248755739 Predicted secreted proteins Evidence at transcript level Tissue enriched Group enriched 12 colon: 220.5;rectum: 143.8 appendix: 15.1 MOGAT2 DGAT2L5, FLJ22644, MGAT2 ENSG00000166391 Monoacylglycerol O-acyltransferase 2 11 75717819-75732958 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA028834 Uncertain Tissue enhanced Group enriched 12 colon: 12.7;duodenum: 38.2;liver: 12.1;rectum: 12.7;small intestine: 44.5 appendix: 2.0 NR1I2 BXR, ONR1, PAR2, PXR, SXR ENSG00000144852 Nuclear receptor subfamily 1, group I, member 2 3 119780484-119818485 FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA029309, HPA055121, HPA073926 Validated Nucleoplasm Group enriched Group enriched 12 colon: 9.3;duodenum: 23.2;gallbladder: 6.0;liver: 19.7;rectum: 9.4;small intestine: 26.3 stomach: 1.3 SLC39A5 ENSG00000139540 Solute carrier family 39 (zinc transporter), member 5 12 56230049-56237846 Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA018423 Approved Nucleoplasm
Vesicles
Cytosol Renal cancer:5.05e-4 (favourable) Tissue enhanced Group enriched 12 colon: 74.5;duodenum: 247.0;kidney: 114.6;liver: 85.7;pancreas: 53.1;rectum: 49.7;small intestine: 245.4 gallbladder: 10.0 C10orf99 AP-57, CSBF, FLJ21763, RLLV1833, UNQ1833 ENSG00000188373 Chromosome 10 open reading frame 99 10 84173738-84185294 Predicted secreted proteins Evidence at protein level HPA050920 Supported Renal cancer:1.20e-5 (unfavourable) Mixed Group enriched 11 colon: 243.3;esophagus: 186.2;rectum: 268.3 urinary bladder: 21.5 CHP2 ENSG00000166869 Calcineurin-like EF-hand protein 2 16 23754627-23758951 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB072806 Approved Tissue enhanced Group enriched 10 colon: 121.4;duodenum: 259.0;rectum: 130.7;skin: 144.2;small intestine: 232.0 cervix, uterine: 17.4 GLRA2 GLR ENSG00000101958 Glycine receptor, alpha 2 X 14529298-14731812 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB070422 Approved Mixed Group enriched 10 cerebral cortex: 6.2;colon: 1.4;rectum: 4.3 testis: 0.3 HHLA2 B7-H5, B7H7, B7y ENSG00000114455 HERV-H LTR-associating 2 3 108296490-108378285 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA055478 Approved Group enriched Group enriched 10 colon: 89.3;duodenum: 89.6;gallbladder: 46.3;rectum: 92.1;small intestine: 146.8 stomach: 9.3 ATOH1 bHLHa14, HATH1, MATH-1, Math1 ENSG00000172238 Atonal bHLH transcription factor 1 4 93828753-93830964 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at transcript level Colorectal cancer:3.26e-5 (favourable) Tissue enhanced Group enriched 9 colon: 18.0;duodenum: 11.4;rectum: 20.1;small intestine: 22.8 appendix: 2.0 CDHR5 FLJ20219, MU-PCDH, MUCDHL, MUPCDH ENSG00000099834 Cadherin-related family member 5 11 616565-626078 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA009081, HPA009173, CAB025004 Supported Group enriched Group enriched 9 colon: 42.5;duodenum: 85.2;kidney: 23.4;liver: 20.6;rectum: 55.1;small intestine: 65.8 gallbladder: 5.3 CDX1 ENSG00000113722 Caudal type homeobox 1 5 150166795-150184558 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA055196 Supported Tissue enhanced Group enriched 9 colon: 132.2;duodenum: 66.3;rectum: 137.0;small intestine: 107.0 appendix: 12.7 NXPE4 C11orf33, FAM55D, FLJ20127 ENSG00000137634 Neurexophilin and PC-esterase domain family, member 4 11 114570591-114595762 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA042801 Approved Tissue enriched Group enriched 9 colon: 142.1;rectum: 161.0;salivary gland: 38.4 appendix: 12.4 REG4 GISP, REG-IV, RELP ENSG00000134193 Regenerating islet-derived family, member 4 1 119794018-119811660 Predicted secreted proteins Evidence at protein level CAB025867, HPA046555 Supported Group enriched Group enriched 9 colon: 222.4;duodenum: 246.1;rectum: 304.0;small intestine: 676.7 appendix: 41.2 TMEM236 bA162I21.2, bA16O1.2, FAM23A, FAM23B ENSG00000148483 Transmembrane protein 236 10 17752252-17800868 Predicted membrane proteins Evidence at transcript level Tissue enhanced Group enriched 9 colon: 14.7;duodenum: 22.7;rectum: 15.8;small intestine: 38.4 appendix: 2.4 CLCA1 CaCC, CLCRG1 ENSG00000016490 Chloride channel accessory 1 1 86468368-86500289 Predicted secreted proteins, Transporters Evidence at protein level HPA052787, HPA059301 Supported Colorectal cancer:2.98e-4 (favourable) Group enriched Group enriched 8 colon: 713.1;duodenum: 906.3;rectum: 1141.9;small intestine: 1551.5 appendix: 139.7 CLRN3 MGC32871, TMEM12, USH3AL1 ENSG00000180745 Clarin 3 10 127877841-127892947 Predicted membrane proteins, Transporters Evidence at protein level HPA014482 Approved Stomach cancer:8.98e-4 (favourable) Group enriched Group enriched 8 colon: 71.2;duodenum: 75.4;gallbladder: 23.7;kidney: 43.9;liver: 40.2;rectum: 77.5;small intestine: 99.5 appendix: 7.5 DHRS11 MGC4172, SDR24C1 ENSG00000278535 Dehydrogenase/reductase (SDR family) member 11 17 36591798-36600806 Predicted intracellular proteins Evidence at protein level HPA041226, HPA048236, HPA053623 Supported Approved Golgi apparatus
Cytosol Renal cancer:3.24e-4 (favourable) Expressed in all Group enriched 8 colon: 45.4;duodenum: 153.7;rectum: 47.9;small intestine: 136.4 testis: 11.8 GAL3ST2 GP3ST ENSG00000154252 Galactose-3-O-sulfotransferase 2 2 241776825-241804208 Predicted secreted proteins Evidence at protein level HPA071809 Supported Group enriched Group enriched 8 colon: 9.5;rectum: 4.1 appendix: 0.9 GPA33 A33 ENSG00000143167 Glycoprotein A33 (transmembrane) 1 167052836-167166479 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018858, CAB025943 Supported Tissue enriched Group enriched 8 colon: 186.8;duodenum: 134.3;rectum: 191.4;small intestine: 133.9 appendix: 19.9 HOXD13 HOX4I, SPD ENSG00000128714 Homeobox D13 2 176092891-176095938 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA064064 Supported Nucleus Colorectal cancer:6.95e-5 (unfavourable) Mixed Group enriched 8 cervix, uterine: 7.9;colon: 5.1;prostate: 18.4;rectum: 9.6;seminal vesicle: 24.4 urinary bladder: 1.6 LRRC19 FLJ21302 ENSG00000184434 Leucine rich repeat containing 19 9 26993136-27005693 Predicted membrane proteins Evidence at protein level Renal cancer:7.08e-8 (favourable) Group enriched Group enriched 8 colon: 36.8;duodenum: 24.4;gallbladder: 9.5;kidney: 45.4;rectum: 36.2;small intestine: 35.4 appendix: 3.7 AC011513.3 ENSG00000267881 19 41708612-41761282 Predicted secreted proteins Evidence at transcript level HPA011041 Approved Tissue enhanced Group enriched 7 colon: 42.9;esophagus: 10.4 appendix: 3.7 CDH17 cadherin, HPT-1 ENSG00000079112 Cadherin 17, LI cadherin (liver-intestine) 8 94127171-94217303 Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA023614, HPA023616, CAB025143, HPA026556 Supported Supported Cell Junctions Group enriched Group enriched 7 colon: 261.7;duodenum: 323.0;rectum: 272.5;small intestine: 300.5 appendix: 39.2 CEACAM7 CEA, CGM2 ENSG00000007306 Carcinoembryonic antigen-related cell adhesion molecule 7 19 41673307-41706976 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA069621 Supported Tissue enhanced Group enriched 7 colon: 592.8;rectum: 701.8 appendix: 95.9 FABP1 L-FABP ENSG00000163586 Fatty acid binding protein 1, liver 2 88122982-88128116 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002305, HPA028275 Supported Approved Nucleoplasm
Cytosol Group enriched Group enriched 7 colon: 4641.2;duodenum: 4243.6;liver: 5656.0;rectum: 3161.5;small intestine: 4603.3 kidney: 599.7 FSIP1 FLJ35989 ENSG00000150667 Fibrous sheath interacting protein 1 15 39600031-39782830 Predicted intracellular proteins Evidence at protein level HPA041002 Uncertain Uncertain Nucleoplasm Tissue enriched Group enriched 7 colon: 11.3;rectum: 18.6;testis: 13.5 breast: 2.1 GALNT8 GALNAC-T8 ENSG00000130035 Polypeptide N-acetylgalactosaminyltransferase 8 12 4720341-4851927 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA012638, HPA014418, HPA073461 Approved Approved Vesicles Tissue enhanced Group enriched 7 cerebral cortex: 19.5;colon: 18.0;duodenum: 8.4;rectum: 41.3;small intestine: 19.3;testis: 26.3 appendix: 3.3 HNF4A HNF4, MODY, MODY1, NR2A1, TCF14 ENSG00000101076 Hepatocyte nuclear factor 4, alpha 20 44355700-44434596 Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA004712, CAB019417 Supported Supported Nucleoplasm Tissue enhanced Group enriched 7 colon: 58.9;duodenum: 105.9;kidney: 44.3;liver: 50.9;rectum: 48.5;small intestine: 92.8;stomach: 22.1 gallbladder: 9.2 NEU4 ENSG00000204099 Sialidase 4 2 241808825-241817413 Enzymes, Predicted intracellular proteins Evidence at protein level HPA037394, HPA037395 Uncertain Group enriched Group enriched 7 bone marrow: 2.4;cerebral cortex: 6.4;colon: 8.5;duodenum: 5.7;liver: 4.1;rectum: 3.9;small intestine: 5.4 gallbladder: 0.8 PHGR1 ENSG00000233041 Proline/histidine/glycine-rich 1 15 40351033-40356434 Predicted intracellular proteins Evidence at protein level HPA068787 Supported Approved Vesicles Breast cancer:2.05e-4 (favourable) Group enriched Group enriched 7 colon: 1475.8;duodenum: 917.9;rectum: 408.6;small intestine: 1813.6 stomach: 170.7 PPP1R14D CPI17-like, FLJ20251, GBPI-1, MGC119014, MGC119016 ENSG00000166143 Protein phosphatase 1, regulatory (inhibitor) subunit 14D 15 40815445-40828709 Predicted intracellular proteins Evidence at protein level HPA041846 Uncertain Renal cancer:3.07e-4 (unfavourable) Tissue enhanced Group enriched 7 colon: 107.5;duodenum: 114.3;gallbladder: 24.3;rectum: 101.6;small intestine: 91.7 appendix: 12.9 SH2D7 LOC646892 ENSG00000183476 SH2 domain containing 7 15 78077808-78104909 Predicted intracellular proteins Evidence at transcript level HPA051320 Approved Mixed Group enriched 7 colon: 1.7;duodenum: 2.2;small intestine: 1.9;testis: 5.7 cerebral cortex,rectum: 0.4 VIL1 D2S1471, VIL ENSG00000127831 Villin 1 2 218419092-218453295 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002452, HPA006884, HPA006885 Supported Supported Plasma membrane Tissue enhanced Group enriched 7 colon: 175.1;duodenum: 409.9;rectum: 199.9;small intestine: 489.9 gallbladder: 44.9 AMN amnionless ENSG00000166126 Amnion associated transmembrane protein 14 102922656-102933596 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000817 Approved Renal cancer:9.62e-5 (favourable) Mixed Group enriched 6 colon: 20.4;duodenum: 35.1;kidney: 29.0;small intestine: 72.0 liver,stomach: 6.8 BTNL8 BTN9.2, FLJ21458 ENSG00000113303 Butyrophilin-like 8 5 180899077-180950906 Predicted membrane proteins Evidence at protein level HPA039738 Approved Group enriched Group enriched 6 colon: 26.5;duodenum: 120.7;rectum: 28.2;small intestine: 96.1 gallbladder: 10.5 CASP5 ICE(rel)III ENSG00000137757 Caspase 5, apoptosis-related cysteine peptidase 11 104994235-105023168 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA040937 Uncertain Group enriched Group enriched 6 appendix: 20.7;colon: 16.2;duodenum: 10.4;rectum: 14.7;small intestine: 19.3 smooth muscle: 2.6 CDX2 CDX3 ENSG00000165556 Caudal type homeobox 2 13 27962137-27971139 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB002221, HPA045669, HPA049580 Supported Supported Nucleoplasm Tissue enriched Group enriched 6 colon: 31.4;duodenum: 22.9;rectum: 25.3;small intestine: 30.8 appendix: 4.9 CEACAM6 CD66c, NCA ENSG00000086548 Carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) 19 41750977-41772208 Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB008370, HPA011041 Supported Mixed Group enriched 6 bone marrow: 110.9;colon: 184.1;esophagus: 174.2;gallbladder: 190.2;lung: 406.1;rectum: 236.9 appendix: 38.9 CLCA4 CaCC2 ENSG00000016602 Chloride channel accessory 4 1 86547078-86580754 Predicted membrane proteins Evidence at protein level HPA017045 Uncertain Colorectal cancer:7.47e-4 (favourable), Head and neck cancer:8.63e-4 (favourable) Tissue enhanced Group enriched 6 colon: 253.7;esophagus: 366.8;rectum: 160.8 urinary bladder: 42.4 EFNA2 ELF-1, EPLG6, LERK6 ENSG00000099617 Ephrin-A2 19 1286154-1300237 Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB005178 Uncertain Tissue enhanced Group enriched 6 colon: 7.1;duodenum: 8.2;small intestine: 10.8 rectum: 1.5 EPS8L3 FLJ21522, MGC16817 ENSG00000198758 EPS8-like 3 1 109750080-109764027 Predicted intracellular proteins Evidence at protein level HPA030998 Approved Approved Vesicles Renal cancer:2.52e-5 (unfavourable), Liver cancer:4.13e-5 (unfavourable), Urothelial cancer:1.82e-4 (favourable) Group enriched Group enriched 6 colon: 76.3;duodenum: 156.3;gallbladder: 60.0;rectum: 87.4;small intestine: 170.4;stomach: 54.0 appendix: 15.8 ERN2 IRE1b ENSG00000134398 Endoplasmic reticulum to nucleus signaling 2 16 23690309-23713500 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA016558 Uncertain Mixed Group enriched 6 cervix, uterine: 26.7;colon: 27.8;duodenum: 12.7;gallbladder: 25.2;rectum: 23.4;small intestine: 10.1;stomach: 49.9 appendix: 3.9 IHH BDA1, HHG2 ENSG00000163501 Indian hedgehog 2 219054420-219060467 Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level Endometrial cancer:3.67e-6 (favourable) Tissue enhanced Group enriched 6 cervix, uterine: 8.8;colon: 21.4;duodenum: 15.3;endometrium: 31.4;rectum: 16.9;small intestine: 16.8;stomach: 15.6 appendix,prostate: 3.1 LRRC26 bA350O14.10 ENSG00000184709 Leucine rich repeat containing 26 9 137168758-137170051 Predicted membrane proteins Evidence at protein level HPA056312 Approved Supported Plasma membrane Endometrial cancer:4.82e-6 (favourable), Stomach cancer:3.48e-4 (favourable) Tissue enriched Group enriched 6 colon: 10.5;prostate: 29.3;salivary gland: 26.7 small intestine: 3.6 MISP C19orf21, Caprice, DKFZp686H18209 ENSG00000099812 Mitotic spindle positioning 19 751126-764318 Predicted intracellular proteins Evidence at protein level HPA049511, HPA062232 Supported Validated Plasma membrane
Focal adhesion sites Tissue enhanced Group enriched 6 colon: 96.4;duodenum: 178.1;rectum: 53.5;small intestine: 221.5 stomach: 22.1 MOGAT3 DC7, MGAT3 ENSG00000106384 Monoacylglycerol O-acyltransferase 3 7 101195007-101201021 Enzymes, Predicted membrane proteins Evidence at protein level HPA011940 Uncertain Approved Centrosome Tissue enhanced Group enriched 6 colon: 11.5;duodenum: 31.2;rectum: 12.0;small intestine: 34.2 liver: 3.4 MUC13 DRCC1 ENSG00000173702 Mucin 13, cell surface associated 3 124905442-124953819 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA045163 Supported Renal cancer:9.73e-5 (unfavourable) Tissue enhanced Group enriched 6 colon: 307.7;duodenum: 631.7;rectum: 335.1;small intestine: 567.0 appendix: 82.8 SATB2 FLJ21474, KIAA1034 ENSG00000119042 SATB homeobox 2 2 199269500-199471266 Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA001042, CAB023669, HPA029543, CAB062562, CAB067751, CAB068229, CAB068230, CAB068231 Supported Supported Nucleoplasm Renal cancer:5.37e-8 (favourable) Tissue enhanced Group enriched 6 cerebral cortex: 22.8;colon: 37.7;rectum: 48.3 small intestine: 6.5 SLC17A4 KIAA2138 ENSG00000146039 Solute carrier family 17, member 4 6 25754699-25781191 Predicted membrane proteins, Transporters Evidence at transcript level HPA055564 Approved Group enriched Group enriched 6 colon: 20.8;duodenum: 29.4;gallbladder: 25.5;liver: 22.4;rectum: 29.4;small intestine: 35.7 pancreas: 4.2 SPINK4 MGC133107, PEC-60 ENSG00000122711 Serine peptidase inhibitor, Kazal type 4 9 33218365-33248567 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA007286 Supported Approved Nucleus
Golgi apparatus
Vesicles Colorectal cancer:8.85e-5 (favourable) Group enriched Group enriched 6 colon: 647.7;duodenum: 273.9;rectum: 1085.3;small intestine: 748.6 appendix: 112.0 TPH1 TPH, TPRH ENSG00000129167 Tryptophan hydroxylase 1 11 18017564-18042426 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB010767, HPA022483 Supported Uncertain Cytosol Mixed Group enriched 6 colon: 9.0;duodenum: 10.5;rectum: 21.3;small intestine: 12.9;stomach: 15.5 prostate: 2.2 TRIM31 C6orf13, HCG1, HCGI, RNF ENSG00000204616 Tripartite motif containing 31 6 30102897-30113106 Predicted intracellular proteins Evidence at protein level HPA046400 Uncertain Group enriched Group enriched 6 colon: 10.1;small intestine: 2.3;stomach: 2.1;urinary bladder: 2.8 duodenum: 0.7 UGT2B15 UGT2B8 ENSG00000196620 UDP glucuronosyltransferase 2 family, polypeptide B15 4 68537413-68670628 Enzymes, Predicted membrane proteins Evidence at protein level HPA045108 Approved Urothelial cancer:4.50e-4 (favourable), Liver cancer:9.82e-4 (favourable) Tissue enriched Group enriched 6 colon: 23.8;duodenum: 30.6;gallbladder: 114.5;liver: 108.6;small intestine: 33.9 stomach: 10.2 ZG16 hZG16, JCLN, JCLN1, ZG16A ENSG00000174992 Zymogen granule protein 16 16 29778240-29782973 Predicted secreted proteins Evidence at protein level HPA052066, HPA052512 Supported Tissue enriched Group enriched 6 colon: 369.7;rectum: 511.8;small intestine: 123.6 duodenum: 59.3 B3GALT5 B3GalT-V, B3T5, beta3Gal-T5, GLCT5 ENSG00000183778 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 5 21 39556442-39673137 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA054092, HPA054684 Approved Endometrial cancer:6.36e-4 (favourable) Mixed Group enriched 5 colon: 23.1;duodenum: 28.2;gallbladder: 8.6;rectum: 41.3;small intestine: 37.9 stomach: 5.1 FOXA3 HNF3G ENSG00000170608 Forkhead box A3 19 45863989-45873797 Predicted intracellular proteins, Transcription factors Evidence at protein level CAB015154, HPA054034 Uncertain Approved Nucleoplasm Mixed Group enriched 5 colon: 17.0;duodenum: 10.6;liver: 32.5;pancreas: 9.8;rectum: 18.2;small intestine: 14.2;stomach: 34.1 gallbladder: 3.6 HAVCR1 CD365, HAVCR, HAVCR-1, TIM-1, TIM1, TIMD1 ENSG00000113249 Hepatitis A virus cellular receptor 1 5 157029413-157059119 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007173 Approved Vesicles Urothelial cancer:1.32e-4 (favourable), Stomach cancer:7.81e-4 (unfavourable) Tissue enriched Group enriched 5 colon: 4.9;kidney: 8.2;rectum: 4.2;testis: 1.7 parathyroid gland: 0.9 IL22RA1 CRF2-9, IL22R ENSG00000142677 Interleukin 22 receptor, alpha 1 1 24119771-24143121 Predicted membrane proteins Evidence at protein level HPA042399 Approved Mixed Group enriched 5 colon: 11.5;duodenum: 20.8;esophagus: 10.2;pancreas: 26.0;rectum: 11.1;skin: 38.8;small intestine: 32.0 gallbladder: 4.0 LRRC31 FLJ23259 ENSG00000114248 Leucine rich repeat containing 31 3 169839179-169869930 Predicted intracellular proteins Evidence at protein level HPA037548 Uncertain Mixed Group enriched 5 colon: 18.5;duodenum: 9.1;rectum: 24.7;small intestine: 11.2;stomach: 9.8 liver: 2.8 NOS2 HEP-NOS, iNOS, NOS, NOS2A ENSG00000007171 Nitric oxide synthase 2, inducible 17 27756766-27800499 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002014 Approved Tissue enhanced Group enriched 5 appendix: 19.6;colon: 7.2;duodenum: 12.6;rectum: 10.0;small intestine: 24.6;urinary bladder: 6.7 smooth muscle: 2.5 SULT1B1 ST1B2 ENSG00000173597 Sulfotransferase family, cytosolic, 1B, member 1 4 69721162-69787961 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA002107 Supported Approved Nucleoplasm
Golgi apparatus Group enriched Group enriched 5 colon: 70.7;duodenum: 101.9;rectum: 69.5;small intestine: 106.2;stomach: 41.6 appendix: 14.6 TRPM5 LTRPC5, MTR1 ENSG00000070985 Transient receptor potential cation channel, subfamily M, member 5 11 2404515-2423045 Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA042115, HPA043315 Approved Tissue enhanced Group enriched 5 colon: 1.0;duodenum: 3.0;epididymis: 2.2;seminal vesicle: 2.5;small intestine: 2.9 testis,thyroid gland: 0.4 URAD PRHOXNB ENSG00000183463 Ureidoimidazoline (2-oxo-4-hydroxy-4-carboxy-5-) decarboxylase 13 27977714-27988654 Enzymes, Predicted intracellular proteins Evidence at transcript level HPA038972 Uncertain Tissue enriched Group enriched 5 colon: 13.0;duodenum: 8.5;small intestine: 18.3 appendix: 2.4 VIP ENSG00000146469 Vasoactive intestinal peptide 6 152750798-152759765 Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA017324, CAB018649, HPA072701 Supported Approved Endoplasmic reticulum Group enriched Group enriched 5 appendix: 215.7;colon: 72.6;rectum: 69.1;small intestine: 53.7;smooth muscle: 57.4 duodenum: 17.3